ルンスミオとポライビーの併用療法、再発又は難治性の大細胞型B細胞リンパ腫に対する適応追加の承認を取得
再発又は難治性の大細胞型B細胞リンパ腫に対し、高い奏効割合と無増悪生存期間の延長が確認された新たな治療法として、世界で初めて承認取得 国際共同第III相試験（ SUNMO 試験）において、 R-Gem...
Publisher
Japan
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalIn-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Summary excerpt
再発又は難治性の大細胞型B細胞リンパ腫に対し、高い奏効割合と無増悪生存期間の延長が確認された新たな治療法として、世界で初めて承認取得 国際共同第III相試験（ SUNMO 試験）において、 R-Gem...
Source route
Continue on chugai-pharm.co.jp
Leave the platform to read the original full article on the publisher site.
Source: Chugai Pharmaceutical News
Scope: Industry
Related coverage
More related coverage
Mar.26.2026R & DOno Pharma Submits an Application for Approval of Ripretinib (DCC-2618) in Patients with Advanced Gastrointestinal Stromal Tumor in Japan
Application submitted for manufacturing and marketing approval of ripretinib in Japan for the indica...
Denali’s Avlayah Offers Broader Treatment Of Hunter Syndrome, Evidence Of US FDA Flexibility
US FDA Allergenics Staff Sees Single-Trial ‘Default’ As Helpful
Novo And United’s Triple-G Agonist Scores In Diabetes Study
Phase II results follow close behind corresponding study in obesity, but show less to scare Novo Nor...